LEADER 00000cam a2201177Ii 4500 
001    ocn896824700 
003    OCoLC 
005    20200606023921.0 
006    m     o  d         
007    cr cnu|||unuuu 
008    141124t20142015nyu     o     000 0 eng d 
015    GBB8L6694|2bnb 
016 7  019127143|2Uk 
019    900363982|a1005755747|a1012023432 
020    9781493913930|q(electronic bk.) 
020    149391393X|q(electronic bk.) 
020    1493913921 
020    9781493913923 
020    |z9781493913923 
024 7  10.1007/978-1-4939-1393-0|2doi 
035    (OCoLC)896824700|z(OCoLC)900363982|z(OCoLC)1005755747
       |z(OCoLC)1012023432 
037    com.springer.onix.9781493913930|bSpringer Nature 
040    N$T|beng|erda|epn|cN$T|dN$T|dYDXCP|dGW5XE|dIDEBK|dEBLCP
       |dCDX|dZ5A|dESU|dOCLCQ|dCOO|dDKU|dOCLCF|dVT2|dMERER|dNJR
       |dI9W|dI8H|dU3W|dOCLCQ|dIOG|dAU@|dOCLCO|dUKMGB|dOCLCO
       |dOCLCA|dOCLCQ|dWURST|dSRU 
049    STJJ 
050  4 RC643 
072  7 HEA|x039000|2bisacsh 
072  7 MED|x014000|2bisacsh 
072  7 MED|x022000|2bisacsh 
072  7 MED|x112000|2bisacsh 
072  7 MJCL|2bicssc 
072  7 MED|x045000|2bisacsh 
082 04 616.99419|223 
245 00 Targeted therapy of acute myeloid leukemia /|cMichael 
       Andreeff, editor. 
264  1 New York :|bSpringer,|c[2014] 
264  4 |c©2015 
300    1 online resource 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
347    text file|bPDF|2rda 
490 1  Current cancer resarch 
505 0  Introduction/Perspective -- Genetics and Classification of
       Acute Myeloid Leukemia -- Proteomics of AML to guide 
       Selection of Therapy -- Roles of Apoptosis Regulating Bcl-
       2-Family Genes in AML -- Bcl-2 family: Translational 
       aspects -- IAP Family and Proteins as Therapeutic Targets 
       for Acute Myeloid Leukemia -- TP53 Mutations in Acute 
       Myeloid Leukemia -- Targeting p53 Tumor Suppressor for AML
       Therapy -- AML-Selective Apoptosis Induction by rationally
       designed Death Ligand Fusion Protein -- PIM Kinases in AML
       -- Development of Midostaurin as a Tyrosine Kinase 
       Inhabitor -- FLT3 in AML -- FLT3-ITD. Clinical (Sorafenib/
       AC220) -- Nucleophosmin (NPM1) -- Raf/MEK Pathway -- The 
       Role of Translational Medicine in Optimization of 
       Therapies targeting the RAS-MAP Kinase Pathway -- Clinical
       Use of Farnesyltransferase Inhititors -- The P13K-AKT-mTOR
       signaling Network in AML -- Targeting the P13 Kinase-mTOR 
       Signaling Pathway in AML -- Aurora kinases -- The Clinical
       Development of Aurora Kinase Inhibitors in Acute Myeloid 
       Leukemia -- AML-Deacetylases -- Methylation in AML-
       Clinical Applications -- Topic: RARa/RXR Part: Basic -- 
       Arsenic Trioxide in Untreated APL -- Targeting PML-RAR? 
       with Retinoids -- NR4A Orphan Receptors as Drug Targets --
       Antibody-based Therapeutics Targeting CD33, CD45, and CD66
       -- New Heterogeneity of the Leukemic Stem Cells -- 
       Targeting Leukemia Stem Cells -- Regulation of 
       Hematopoiesis by CXCL12/CXCR4 Signaling -- CXC4/CXCL12 as 
       a Therapeutic Target -- VLA-4: A Cell's Consequential 
       Encounter -- VLA-4 Function and Prognosis in Acute Myeloid
       Leukemia -- VLA4 in Acute Lymphoblastic Leukemia -- The 
       Leukemic Bone Marrow Microenvironment: Targeting Hypoxia 
       with Hypoxia Activated Pro-Drugs -- Topic: miRs as 
       Therapeutic Targets -- Clinical Implications of MicroRNAs 
       in AML -- Inhibition of Glycolysis as a Therapeutic 
       Strategy in Acute Myeloid Leukemias -- Molecular and 
       Biochemical Basis for the Reprogramming of Intermediary 
       Metabolism in Leukemia Cells -- NK Cell Immunotherapy for 
       AML -- Allogeneic and Autologous T cell Strategies to 
       Enhance Targeting of Acute Myeloid Leukemia -- Indications
       for Hematopoietic Transplantation for AML -- Mesenchymal 
       Stem/Stromal Cell Targeted Therapies for Solid Tumors and 
       Hematological Malignancies. 
520    This book provides an unprecedented overview of targeted 
       therapies for acute myeloid leukemias. The volume provides
       comprehensive coverage of the diverse therapeutic 
       strategies that have been developed during the last decade
       and are now being evaluated in early clinical trials. 
       Authoritative chapters are written by leading research 
       scientists and clinicians, who explain basic concepts and 
       the clinical translation of topics that include the 
       underlying genetic and proteomic abnormalities of AML. The
       chapter topics include the development of novel nucleoside
       analogues, the roles of microRNAs, apoptosis regulators 
       Bcl-2 and p53, and of critical cell signaling proteins 
       such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora 
       kinases. In addition, chapters on epigenetic mechanisms, 
       nuclear receptors, cell surface antigens, the hypoxic 
       leukemia microenvironment, stem cells, and leukemia 
       metabolism, provide insight into leukemia cell 
       vulnerabilities. Cell therapies utilizing T-, NK- and 
       mesenchymal stem cells and progress in hematopoietic 
       transplantation strategies complete the overview of the 
       multi-dimensional therapeutic landscape, where℗ℓ leukemia 
       specialists develop treatment strategies, which are 
       expected to bring forth critical breakthroughs in the 
       field of leukemia.℗ℓ 
650  0 Acute myeloid leukemia|xTreatment. 
650  2 Leukemia, Myeloid.|0(DNLM)D007951 
650  2 Investigative Techniques 
650  2 Drug Therapy.|0(DNLM)D004358 
650  2 Therapeutics.|0(DNLM)D013812 
650  2 Analytical, Diagnostic and Therapeutic Techniques and 
       Equipment 
650  2 Leukemia.|0(DNLM)D007938 
650  2 Neoplasms by Histologic Type 
650  2 Disease.|0(DNLM)D004194 
650  2 Leukemia, Myeloid, Acute.|0(DNLM)D015470 
650  2 Molecular Targeted Therapy.|0(DNLM)D058990 
650  2 Methods.|0(DNLM)D008722 
650  2 Neoplasms.|0(DNLM)D009369 
650  4 Health & Biological Sciences. 
650  4 Oncology. 
650  4 Medicine. 
650  7 Pharmacology.|2bicssc 
650  7 Cellular biology (cytology)|2bicssc 
650  7 Microbiology (non-medical)|2bicssc 
650  7 Oncology.|2bicssc 
650  7 HEALTH & FITNESS|xDiseases|xGeneral.|2bisacsh 
650  7 MEDICAL|xClinical Medicine.|2bisacsh 
650  7 MEDICAL|xDiseases.|2bisacsh 
650  7 MEDICAL|xEvidence-Based Medicine.|2bisacsh 
650  7 MEDICAL|xInternal Medicine.|2bisacsh 
650  7 Cytology.|2fast|0(OCoLC)fst00886282 
650  7 Medicine.|2fast|0(OCoLC)fst01014893 
650  7 Microbiology.|2fast|0(OCoLC)fst01019576 
650  7 Oncology.|2fast|0(OCoLC)fst01045739 
650  7 Toxicology.|2fast|0(OCoLC)fst01153364 
653 00 farmacologie 
653 00 pharmacology 
653 00 toxicologie 
653 00 toxicology 
653 00 celbiologie 
653 00 cellular biology 
653 00 biomedische wetenschappen 
653 00 biomedicine 
653 00 neoplasms 
653 00 microbiologie 
653 00 microbiology 
653 10 Medicine (General) 
653 10 Geneeskunde (algemeen) 
655  4 Electronic books. 
700 1  Andreeff, Michael,|d1943-|eeditor. 
776 08 |iPrinted edition:|z9781493913923 
830  0 Current cancer research. 
880 0  |6505-00|aIntroduction/Perspective -- Genetics and 
       Classification of Acute Myeloid Leukemia -- Proteomics of 
       AML to guide Selection of Therapy -- Roles of Apoptosis 
       Regulating Bcl-2-Family Genes in AML -- Bcl-2 family: 
       Translational aspects -- IAP Family and Proteins as 
       Therapeutic Targets for Acute Myeloid Leukemia -- TP53 
       Mutations in Acute Myeloid Leukemia -- Targeting p53 Tumor
       Suppressor for AML Therapy -- AML-Selective Apoptosis 
       Induction by rationally designed Death Ligand Fusion 
       Protein -- PIM Kinases in AML -- Development of 
       Midostaurin as a Tyrosine Kinase Inhabitor -- FLT3 in AML 
       -- FLT3-ITD. Clinical (Sorafenib/AC220) -- Nucleophosmin 
       (NPM1) -- Raf/MEK Pathway -- The Role of Translational 
       Medicine in Optimization of Therapies targeting the RAS-
       MAP Kinase Pathway -- Clinical Use of Farnesyltransferase 
       Inhititors -- The P13K-AKT-mTOR signaling Network in AML -
       - Targeting the P13 Kinase-mTOR Signaling Pathway in AML -
       - Aurora kinases -- The Clinical Development of Aurora 
       Kinase Inhibitors in Acute Myeloid Leukemia -- AML-
       Deacetylases -- Methylation in AML-Clinical Applications -
       - Topic: RARa/RXR Part: Basic -- Arsenic Trioxide in 
       Untreated APL -- Targeting PML-RARα with Retinoids -- NR4A
       Orphan Receptors as Drug Targets -- Antibody-based 
       Therapeutics Targeting CD33, CD45, and CD66 -- New 
       Heterogeneity of the Leukemic Stem Cells -- Targeting 
       Leukemia Stem Cells -- Regulation of Hematopoiesis by 
       CXCL12/CXCR4 Signaling -- CXC4/CXCL12 as a Therapeutic 
       Target -- VLA-4: A Cell's Consequential Encounter -- VLA-4
       Function and Prognosis in Acute Myeloid Leukemia -- VLA4 
       in Acute Lymphoblastic Leukemia -- The Leukemic Bone 
       Marrow Microenvironment: Targeting Hypoxia with Hypoxia 
       Activated Pro-Drugs -- Topic: miRs as Therapeutic Targets 
       -- Clinical Implications of MicroRNAs in AML -- Inhibition
       of Glycolysis as a Therapeutic Strategy in Acute Myeloid 
       Leukemias -- Molecular and Biochemical Basis for the 
       Reprogramming of Intermediary Metabolism in Leukemia Cells
       -- NK Cell Immunotherapy for AML -- Allogeneic and 
       Autologous T cell Strategies to Enhance Targeting of Acute
       Myeloid Leukemia -- Indications for Hematopoietic 
       Transplantation for AML -- Mesenchymal Stem/Stromal Cell 
       Targeted Therapies for Solid Tumors and Hematological 
       Malignancies. 
994    C0|bSTJ